Company: HRTX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-060882
Chunk: 31

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 31
---
2025.

Consists of (i) 6,986,744 shares held indirectly through Velan Capital Master Fund LP, (ii) 605,974 pre-funded warrants to purchase common stock held indirectly through Velan Capital Master Fund LP, (iii) 32,888 shares of common stock, (iv) 15,454 shares of common stock underlying stock options exercisable within 60 days of April 21, 2025 and (v) 2,367 shares of common stock underlying restricted stock units vesting within 60 days of April 21, 2025. In addition, Mr. Morgan holds (indirectly through Velan Capital Master Fund LP) pre-funded warrants to purchase 556,917 shares of common stock which are not exercisable within 60 days of April 21, 2025. Mr. Morgan is considered a beneficial owner of the shares held indirectly through Velan Capital Master Fund LP, as Mr. Morgan is a partner and Chief Investment Officer of Velan Capital.

Consists of 68,449 shares of common stock, 7,546 shares of common stock underlying stock options exercisable within 60 days of April 21, 2025, and 390 shares of common stock underlying restricted stock units vesting within 60 days of April 21, 2025.

Consists of 66,180 shares of common stock and 5,984 shares of common stock underlying stock options exercisable within 60 days of April 21, 2025.

Consists of 8,504,422 shares of common stock, 410,354 shares of common stock underlying stock options exercisable within 60 days of April 21, 2025 and 91,059 shares of common stock underlying restricted stock units vesting within 60 days of April 21, 2025.

22

<div align='center'>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</div>

Related Person Transactions Policies

Pursuant to our Code of Ethics and Business Conduct, our executive officers, directors and employees must disclose transactions involving actual or apparent conflicts of interest, such as related person transactions, to the Chairman of the Board. Additionally, the Audit Committee is responsible for review and approval of all related person transactions in which any officer, director or stockholder has a direct or indirect interest and would be required to be disclosed under Items 404(a) and 404(d) of Regulation S-K, and has written policies and procedures for reviewing, approving or